CURXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Curanex Pharmaceuticals Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$4.92+0.30 (+6.49%)

Close on Oct 19, 2026

Market cap: $139.55M
P/E (TTM): –
Dividend yield: –

Curanex Pharmaceuticals Inc cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	Q2 2026 2026-06-30	Q1 2026 2026-03-31	Q4 2025 2025-12-31	Q3 2025 2025-09-30	Q2 2025 2025-06-30	Q1 2025 2025-03-31	Q4 2024 2024-12-31	Q3 2024 2024-09-30
Stock-Based Compensation	0	0.01	–	–	–	–	–	–
Change in Accounts Payable	-0.01	0.01	-0.11	0.11	-0.13	0.12	0	–
Operating Cash Flow	-1.08	-0.95	-0.86	-9.19	-0.29	-0.15	-0.10	-0.13
Stock Issued	–	–	–	–	–	–	0	0
Financing Cash Flow	–	–	0	15	0.20	0.20	0	0

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -72.1%

Financial strength

Current ratio: 45.95
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2817.2%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 29.15
Dividend yield: –